GOP senators press for generic vaccines

Republican senators are calling on the Department of Health and Human Services to release documents that would let the medical industry bring generic vaccines and tissue products to market.

Medical products made from living cells such as vaccines and skin grafts are known as biologics, and their generic versions are called biosimilars.

“The [Food and Drug Administration] has not yet issued guidance on some of the key scientific policy questions related to biosimilars, such as naming, labeling, indication extrapolation, and interchangeability,” Sens. Orrin HatchOrrin Grant HatchRead Senate GOP's tax bill Senate panel to start tax bill markup on Monday Senate set for clash with House on tax bill MORE (R-Utah) and Lamar AlexanderAndrew (Lamar) Lamar AlexanderObamaCare becomes political weapon for Democrats Senate passes resolution requiring mandatory sexual harassment training Sen. Warren sold out the DNC MORE (R-Tenn.) wrote in a letter to Health and Human Services Secretary Sylvia BurwellSylvia Mathews BurwellPrice was a disaster for HHS — Time for an administrator, not an ideologue Overnight Healthcare: GOP chairman to introduce pre-existing condition bill ObamaCare enrollment hits 11.5M for 2017 MORE.

“We urge you and those within your Department to immediately release guidance pending within the HHS related to the implementation of the biosimilar pathway,” they added.

Biosimilars have been in wide use in Europe and according to Express Scripts, the largest pharmacy benefit management company, their wider use could save the U.S. healthcare system more than $250 billion in the next few years.

Last week the FDA said it was reviewing Sandoz’s biosimilar Zarzio, which could reduce infections in cancer patients. If approved, it would be the first biosimilar to hit the U.S. market and open the floodgates for similar products.

“We assume that FDA and Sandoz had conversations about key issues … and that the FDA is engaged in conversations with other manufacturers who intend to file biosimilar applications in the future,” the two GOP lawmakers wrote.

They noted the FDA is required to release guidance to industry under the 2010 Biologics Price Competition and Innovation Act (BPCIA) but has yet to do so.

“These meetings should not be the only or primary means by which BPCIA implementation policies are developed,” they added. “Does the FDA intend to approve the first biosimilar before policies on these key scientific questions are publicly released?”

Sens. Richard BurrRichard Mauze BurrJuan Williams: The shame of Trump's enablers Five takeaways from the social media hearings Overnight Tech: Senators demand tech firms do more on Russian meddling | House Intel releases Russian-promoted ads | Apple CEO says 'fake news' bigger threat than ads | Ex-Yahoo CEO, Equifax execs to testify on breaches MORE (R-N.C.), Mike EnziMichael (Mike) Bradley EnziGOP senators ask Trump for meeting on biofuels mandate Senate budget just the latest attack on seniors Week ahead: GOP's next steps on tax reform | Fed chief speculation heats up | Senate to vote on disaster relief MORE (R-Wyo.) and Pat RobertsCharles (Pat) Patrick RobertsSenate passes resolution requiring mandatory sexual harassment training Overnight Energy: Perry takes heat for sexual assault comments | Clovis withdraws nomination for USDA post | Battle lines drawn on Arctic refuge drilling | Energy regulator back to full strength Trump USDA pick linked to Mueller probe withdraws nomination MORE (R-Kan.) also signed the letter.